Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Seminars in Arthritis & Rheumatism

• Publication date

  2004-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/S0049-0172(03)00137-9PMID 14978665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever

  2002cited by this paper
• Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population

  2001cited by this paper
• Familial Mediterranean fever: prevalence, penetrance and genetic drift

  2001cited by this paper
• Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state.

  2001cited by this paper
• Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever.

  2000cited by this paper
• Familial Mediterranean fever: high gene frequency and heterogeneous disease among an Israeli-Arab population.

  2000cited by this paper
• Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups

  2000cited by this paper
• MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications.

  1999cited by this paper
• MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever.

  1999cited by this paper
• Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population.

  1999cited by this paper
• Phenotype–genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis

  1999cited by this paper
• Does the lack of the P-glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases?

  1998cited by this paper
• Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.

  1998cited by this paper
• Clinical differences between North African and Iraqi Jews with familial Mediterranean fever.

  1998cited by this paper
• Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

  1997cited by this paper
• Criteria for the diagnosis of familial Mediterranean fever.

  1997cited by this paper
• Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis

  1997cited by this paper
• A candidate gene for familial Mediterranean fever

  1997cited by this paper
• The changing face of familial Mediterranean fever.

  1996cited by this paper
• P-glycoprotein expression and function in circulating blood cells from normal volunteers.

  1994cited by this paper
• Colchicine concentration in leukocytes of patients with familial Mediterranean fever.

  1994cited by this paper
• Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome.

  1994cited by this paper
• Colchicine disposition in human leukocytes after single and multiple oral administration

  1993cited by this paper
• Familial Mediterranean fever in children.

  1992cited by this paper
• Colchicine has opposite effects on interleukin-1β and tumor necrosis factor-α production

  1991cited by this paper
• An in vitro approach to study cellular kinetics of drugs.

  1987cited by this paper
• Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

  1986cited by this paper
• Plasma colchicine concentration in patients with recurrent polyserositis (familial Mediterranean fever) on long-term prophylaxis.

  1982cited by this paper
• Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups.

  1982cited by this paper
• Correction of a suppressor cell deficiency in familial Mediterranean fever by colchicine.

  1981cited by this paper
• Suppressor cell function in a family with familial Mediterranean fever.

  1981cited by this paper
• A sensitive radioimmunoassay for colchicine

  1980cited by this paper
• Colchicine kinetics in patients with familial Mediterranean fever

  1980cited by this paper
• Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever.

  1976cited by this paper
• A controlled trial of colchicine in preventing attacks of familial mediterranean fever.

  1974cited by this paper
• Colchicine for familial Mediterranean fever.

  1972cited by this paper
• Isolation of mononuclear cells and granulocytes from human blood.

  1968cited by this paper
• Familial Mediterranean fever. A survey of 470 cases and review of the literature.

  1967cited by this paper
• FAMILIAL MEDITERRANEAN FEVER

  1959cited by this paper

• Assessment of colchicine adherence and influencing factors in paediatric familial Mediterranean fever.

  2026cites this paper
• EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (FMF): 2024 update.

  2025cites this paper
• Combining Colchicine and Antiplatelet Therapy to Tackle Atherothrombosis: A Paradigm in Transition?

  2025cites this paper
• A single dose of anakinra for arresting familial Mediterranean fever attacks: a proof-of-concept study.

  2024cites this paper
• The possible anti-inflammatory effect of extra virgin olive oil with colchicine in treatment of resistant cases of familial Mediterranean fever in a cohort of pediatric Egyptian patients

  2024cites this paper
• Severity scores, damage indices and the concept of the colchicine-resistant patient in familial Mediterranean fever.

  2024cites this paper
• Recent Insights in Pyrin Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin-Associated Autoinflammatory Syndromes

  2023cites this paper
• Genetic and Epigenetic Regulation of MEFV Gene and Their Impact on Clinical Outcome in Auto-Inflammatory Familial Mediterranean Fever Patients

  2023cites this paper
• PREDICT-crFMF score: a novel model for predicting colchicine resistance in children with familial Mediterranean fever.

  2023cites this paper
• Genotype-Phenotype Associations of Children With Familial Mediterranean Fever in a Cohort Consisting of M694V Mutation and Implications for Colchicine-Resistant Disease

  2023cites this paper
• Arterial Stiffness and Ambulatory Blood Pressure Measurements in Children With Familial Mediterranean Fever

  2023cites this paper
• Interventions for reducing inflammation in familial Mediterranean fever.

  2022cites this paper
• Colchicine resistance: Associated factors and its effect on health‐related quality of life in patients with familial Mediterranean fever

  2022cites this paper
• The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease

  2022influential citation
• Evaluation of the Relationship between Simple Hemogram Indexes and Disease Severity Scores in Pediatric Familial Mediterranean Fever

  2022cites this paper
• Subclinical Atherosclerosis and Oxidized LDL Levels in Familial Mediterranean Fever

  2022cites this paper
• Hereditary Systemic Autoinflammatory Diseases: Therapeutic Stratification

  2022cites this paper
• Tocilizumab for the Treatment of Familial Mediterranean Fever—A Randomized, Double-Blind, Placebo-Controlled Phase II Study

  2022cites this paper
• Early Predictors of Colchicine Resistance in Familial Mediterranean Fever.

  2022cites this paper
• Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.

  2021cites this paper
• Phenotypical and Functional Characterization of Neutrophils in Two Pyrin-Associated Auto-inflammatory Diseases

  2021cites this paper
• The efficacy of interleukin‐1 antagonist
drugs in combination with colchicine in patients with FMF‐AA with colchicine resistance after kidney transplantation: A study with histopathologic evidence

  2021cites this paper
• Colchicine — From rheumatology to the new kid on the block: Coronary syndromes and COVID-19

  2021cites this paper
• Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

  2021cites this paper
• Compliance of Familial Mediterranean Fever Patients With Regular Follow-up Visits and Associated Factors

  2020cites this paper
• Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.

  2020cites this paper
• Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy

  2020cites this paper
• Frequency, characteristics, and clinical determinants of ‘prodrome’ in familial Mediterranean fever patients

  2020cites this paper
• The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

  2020cites this paper
• Efficacy of anti-interleukin-1 treatment in colchicine-resistant arthritis in patients with familial Mediterranean fever.

  2020cites this paper
• Detection of Familial Mediterranean Fever attacks by using a connected activity tracker and assessment of impact of attacks to daily physical activities: a pilot study

  2019cites this paper
• Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine

  2019cites this paper
• Safety and efficacy of intravenous Colchicine in children with Familial Mediterranean Fever

  2019cites this paper
• In silico study of colchicine resistance molecular mechanisms caused by tubulin structural polymorphism

  2019cites this paper
• Limites nosologiques entre fièvre méditerranéenne familiale et spondylarthrite juvénile : analyse de trois cohortes rétrospectives françaises

  2019cites this paper
• Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review

  2019cites this paper
• Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

  2019cites this paper
• An Update on Autoinflammatory Diseases: Inflammasomopathies

  2018cites this paper
• Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever

  2018cites this paper
• SEROLOGICAL SCREENING FOR CELIAC DISEASE IN CHILDREN WITH COLCHICINE-RESISTANT FAMILIAL MEDITERRANEAN FEVER.

  2018cites this paper
• Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients

  2018cites this paper
• On demand use of anakinra for attacks of familial Mediterranean fever (FMF)

  2018cites this paper
• Boundaries between familial Mediterranean fever and juvenile spondyloarthritis: Analysis of three French retrospective cohorts.

  2018cites this paper
• Canakinumab treatment in children with familial Mediterranean fever: report from a single center

  2018cites this paper
• Interventions for reducing inflammation in familial Mediterranean fever.

  2018cites this paper
• Canakinumab treatment in renal transplant recipients with familial Mediterranean fever

  2018cites this paper
• Colchicine

  2018cites this paper
• Advances in the Diagnosis and Treatment of Amyloidosis and Related Disorders

  2018cites this paper
• Adult-Onset Autoinflammatory Syndromes.

  2018cites this paper
• Blood group 'A' may have a possible modifier effect on familial Mediterranean fever and blood group '0' may be associated with colchicine resistance.

  2018cites this paper
• Efectividad de infliximab en la fiebre mediterránea familiar resistente a colchicina

  2017cites this paper
• Effectiveness of Infliximab in colchicine resistant familial Mediterranean fever.

  2017cites this paper
• Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients

  2017cites this paper
• Bibliometric Analysis of the Most Cited First One Hundred Manuscripts in Familial Mediterranean Fever

  2017cites this paper
• Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments.

  2017cites this paper
• Mutations of familial Mediterranean fever in Syrian patients and controls: Evidence for high carrier rate

  2017cites this paper
• A Peculiar Case of Abdominal Pain in an Eleven Years Old Child

  2017cites this paper
• Small Intestinal Bacterial Overgrowth Affects the Responsiveness to Colchicine in Familial Mediterranean Fever

  2017cites this paper
• Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2017cites this paper
• Successful Treatment of Familial Mediterranean Fever with Infliximab in aColchicine Resistant Patient

  2017cites this paper
• Late ventricular potentials in familial Mediterranean fever with and without AA amyloidosis.

  2017cites this paper
• A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever

  2017cites this paper
• Non‐response to colchicine in familial Mediterranean fever should be identified accurately

  2017cites this paper
• Familial Mediterranean Fever

  2016cites this paper
• Guidelines for the management and treatment of periodic fever syndromes familial Mediterranean fever.

  2016cites this paper
• Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.

  2016cites this paper
• A position for tumor necrosis factor inhibitors in the management of colchicine-resistant familial Mediterranean fever?

  2016cites this paper
• The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever

  2016cites this paper
• Colchicine, Biologic Agents and More for the Treatment of Familial Mediterranean Fever. The Old, the New, and the Rare.

  2016cites this paper
• Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation

  2016cites this paper
• Familial Mediterranean Fever

  2016cites this paper
• The role of Adalimumab in the Treatment of Colchicine-Resistant Familial Mediterranean Fever

  2016cites this paper
• Diretrizes de conduta e tratamento de síndromes febris periódicas associadas a febre familiar do Mediterrâneo

  2016cites this paper
• Clinical Review: Familial Mediterranean Fever—An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment

  2016cites this paper
• Interventions for reducing inflammation in familial Mediterranean fever.

  2015cites this paper
• Association between colchicine resistance and vitamin D in familial Mediterranean fever

  2015cites this paper
• Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients

  2015cites this paper
• Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children.

  2015cites this paper
• Colchicine as an anti-inflammatory and cardioprotective agent

  2015cites this paper
• The familial Mediterranean fever (FMF) 50 score: does it work in a controlled clinical trial? Re-analysis of the trial of rilonacept for patients with colchicine resistant or intolerant FMF

  2015cites this paper
• Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis.

  2015cites this paper
• Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents

  2015cites this paper
• Treatment of familial Mediterranean fever: colchicine and beyond.

  2014cites this paper
• Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early.

  2014cites this paper
• MEFV Mutations and CYP3A4 Polymorphisms Do Not Predict "Colchicine Responsiveness" in Familial Mediterranean Fever

  2014cites this paper
• The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

  2014cites this paper
• MEFV Mutations and CYP3A4 Polymorphisms Do Not Predict “Colchicine Responsiveness” in Familial Mediterranean Fever

  2014influential citation
• Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.

  2014cites this paper
• Can colchicine response be predicted in familial Mediterranean fever patients?

  2014cites this paper
• Serum lipid changes and insulin resistance in familial Mediterranean fever.

  2014cites this paper
• [Evaluation of frequency and the attacks features of patients with colchicine resistance in FMF].

  2014cites this paper
• Familial Mediterranean Fever: From Pathogenesis to Treatment

  2014cites this paper
• Monogenic autoinflammatory diseases: concept and clinical manifestations.

  2013cites this paper
• Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents

  2013cites this paper
• Clinical Genetic Testing of Periodic Fever Syndromes

  2013cites this paper
• Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues

  2013cites this paper
• IL-1β Biological Treatment of Familial Mediterranean Fever

  2013cites this paper
• Genetische Fiebersyndrome

  2013cites this paper
• Current trends in colchicine treatment in familial Mediterranean fever.

  2013cites this paper
• Evidence-based recommendations for the practical management of Familial Mediterranean Fever.

  2013cites this paper